<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04277260</url>
  </required_header>
  <id_info>
    <org_study_id>SCMCIRB-K2019023-2</org_study_id>
    <nct_id>NCT04277260</nct_id>
  </id_info>
  <brief_title>Molecular Structure and Content of Human Milk Oligosaccharides (HMOs) and Its Effect on Infant Health in China</brief_title>
  <official_title>Study on the Molecular Structure and Content of Human Milk Oligosaccharides (HMOs) in Breast Milk and Its Effect on Infant Health in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heilongjiang Feihe Dairy Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heilongjiang Feihe Dairy Co. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the study, the composition and content of human milk oligosaccharides in premature
      delivery mothers in China will be examined to investigate the differences in oligosaccharide
      concentrations in preterm breast milk from different gestational weeks. This study will fill
      a gap in human milk research in China, provide theoretical basis for the superiority of
      breastfeeding, and provide more powerful nutritional support for the catch-up growth of
      preterm infants
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective:

        1. Analyze and compare the differences in HMOs components among mothers who give birth at
           different gestational weeks;

        2. Longitudinal observation of weekly changes in HMOs concentrations of premature mothers
           within 1 month of delivery;

        3. Validate the association between HMOs components in preterm mothers and fecal intestinal
           flora in infants at 6 months of age.

      Research content

        1. The LC-MS method will be used to detect the content of HMOs in preterm mothers and
           compared with the corresponding components in term breast milk during the postpartum
           period to analyze the effects of different gestational weeks on HMOs;

        2. The intestinal flora 16S rDNA high-throughput sequencing method will be used to
           determine the bacterial gene profile in the fecal DNA samples of infants, and the
           differences between the gestational age groups (term and preterm infants) were compared,
           and the preterm infants in this group were plotted Evolution of intestinal flora within
           6 months of birth;

        3. Use statistical methods to verify the association between HMOs components in preterm
           mothers and the establishment of intestinal flora in infants.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2019</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Human milk oligosaccharide detection</measure>
    <time_frame>Day7-12, Day14-19, Day21-26, Day28-33</time_frame>
    <description>Liquid chromatography-mass spectrometer(LC-MS) will be used to quantitatively detect a total of 15 types of neutral oligosaccharides and acid oligosaccharides in different breast milk samples.
Human milk samples will be collected four times for each mother after delivery (day7-12, day14-19, day21-26, day28-33). Only one series of samples will be collected for each mother, and 30 samples are needed for each group, totaling 480 human milk samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To dectect the intestinal flora with16s RNA high throughput sequencing</measure>
    <time_frame>Day7-12, Day28-33, 3 months and 6 months</time_frame>
    <description>The results of bacterial gene profiles in fecal DNA samples of premature infants at different gestational ages will be analyzed as follows.First, bacterial genomic DNA in feces will be obtained using the QIAamp Fast DNA Stool Mini Kit(51604), and PCR amplification will be performed. After the Miseq library are successfully constructed, cluster preparation and sequencing will be performed with qualified libraries. The data obtained by the machine will be used for biological information analysis. By comparing OTU with database, species annotation will be performed on OTU.Based on OTU and species annotation results, species complexity analysis and inter-group species difference analysis will be carried out.
Neonatal fecal samples will be collected four times for each infant after delivery at day7-12, day28-33, 3 months and 6 months of age. Only one series of samples will be collected from each infant, and 30 samples are needed for each group, totaling 480 fecal samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achieved the body weight of infants</measure>
    <time_frame>Day7-12, Day14-19, Day21-26, Day28-33, 2 months, 3 months, 4months and 6 months.</time_frame>
    <description>Measured the body weight (grams) of infants at 8 time points: Day7-Day12, Day14-Day19, Day21-Day26, Day28-Day33, 2 months, 3 months, 4months and 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achieved the body length of infants</measure>
    <time_frame>Day7-12, Day14-19, Day21-26, Day28-33, 2 months, 3 months, 4months and 6 months.</time_frame>
    <description>Measured the body length (mm) of infants at 8 time points: Day7-Day12, Day14-Day19, Day21-Day26, Day28-Day33, 2 months, 3 months, 4months and 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achieved the head circumference of infants</measure>
    <time_frame>Day7-12, Day14-19, Day21-26, Day28-33, 2 months, 3 months, 4months and 6 months.</time_frame>
    <description>Measured the head circumference (mm) of infants at 8 time points: Day7-Day12, Day14-Day19, Day21-Day26, Day28-Day33, 2 months, 3 months, 4months and 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool status of infants</measure>
    <time_frame>Day7-12, Day14-19, Day21-26, Day28-33, 2 months, 3 months, 4months and 6 months.</time_frame>
    <description>Achieved the stool status( frequency, color, character)of neonatal based on health consultation at 8 time points: Day7-Day12, Day14-Day19, Day21-Day26, Day28-Day33, 2 months, 3 months, 4months and 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average daily formula intake</measure>
    <time_frame>Day7-12, Day14-19, Day21-26, Day28-33, 2 months, 3 months, 4months and 6 months.</time_frame>
    <description>Achieved the average daily formula intake volume at 8 time points: Day7-Day12, Day14-Day19, Day21-Day26, Day28-Day33, 2 months, 3 months, 4months and 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease and medication history</measure>
    <time_frame>6 months</time_frame>
    <description>Record the disease and medication history of infants in each group</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Child Development</condition>
  <arm_group>
    <arm_group_label>Full term delivery</arm_group_label>
    <description>In the cooperative obstetric hospital, 30 cases of full-term delivery healthy mothers and their infants are selected. Each pair of nursing mothers and infants will complete the observation for 6 months. The samples of human milk and newborn feces are the experimental objects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preterm delivery(35-37 weeks)</arm_group_label>
    <description>In the cooperative obstetric hospital, 30 cases of preterm delivery(35-37 weeks) mothers and their infants are selected. Each pair of nursing mothers and infants will complete the observation for 6 months. The samples of human milk and newborn feces are the experimental objects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preterm delivery(32-35 weeks)</arm_group_label>
    <description>In the cooperative obstetric hospital, 30 cases of preterm delivery(32-35 weeks) mothers and their infants are selected. Each pair of nursing mothers and infants will complete the observation for 6 months. The samples of human milk and newborn feces are the experimental objects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preterm delivery(28-32 weeks)</arm_group_label>
    <description>In the cooperative obstetric hospital, 30 cases of preterm delivery(28-32 weeks) mothers and their infants are selected. Each pair of nursing mothers and infants will complete the observation for 6 months. The samples of human milk and newborn feces are the experimental objects.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fecal specimen of infants
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Lactating mothers and infants in cooperative maternity hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  (1) Be healthy, have no acute or chronic diseases, have no severe complications during
             pregnancy

          -  (2) Breastfeeding for more than 6 months and Volunteer to participate in this study
             (signed informed consent)

          -  (3) Age of maternal women: 20~35years

          -  (4) Breast milk is sufficient, and the amount of milk secreted each time is more than
             30ml

          -  (5) No fatal, important organ system deformities and metabolic defects in neonates

        Exclusion Criteria:

          -  (1) for infants: Rescued to death or hospitalized due to critical illness during the
             study period

          -  (2)for lactating mothers: exposure to tobacco and alcohol during lactation, severe
             postpartum depression and other mental and psychological diseases, obesity (BMI&gt; 28),
             use of antibiotics or antimetabolites, mastitis with fever within 7 days before
             specimen collection (T&gt; 38.5 â„ƒ),Suspension or termination of breastfeeding in the
             state of maternal and infant illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>35 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jing Li, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Children's Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei Zhang, PhD</last_name>
    <phone>+86 10 8457 4688</phone>
    <email>zhangwei1@feihe.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai first maternal and infant health care hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Li</last_name>
      <phone>+86 13585683669</phone>
      <email>zzhlq3@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 13, 2020</study_first_submitted>
  <study_first_submitted_qc>February 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>February 17, 2020</last_update_submitted>
  <last_update_submitted_qc>February 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

